Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
ENTX 
Entera Bio Ltd (ENTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/10/2025: ENTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23.62% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 97.22M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 1.71 | 52 Weeks Range 1.50 - 3.22 | Updated Date 12/11/2025 |
52 Weeks Range 1.50 - 3.22 | Updated Date 12/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Earnings Date
Report Date 2025-11-14 | When - | Estimate -0.09 | Actual 0.07 |
Profitability
Profit Margin - | Operating Margin (TTM) -8729.03% |
Management Effectiveness
Return on Assets (TTM) -53.8% | Return on Equity (TTM) -99.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 88854353 | Price to Sales(TTM) 784.01 |
Enterprise Value 88854353 | Price to Sales(TTM) 784.01 | ||
Enterprise Value to Revenue 716.57 | Enterprise Value to EBITDA -1.52 | Shares Outstanding 45857242 | Shares Floating 31657547 |
Shares Outstanding 45857242 | Shares Floating 31657547 | ||
Percent Insiders 24.21 | Percent Institutions 20.05 |
Upturn AI SWOT
Entera Bio Ltd
Company Overview
History and Background
Entera Bio Ltd. was founded in 2014. The company is a clinical-stage biopharmaceutical company focused on developing orally administered peptide therapeutics. A significant milestone includes its initial public offering (IPO) on NASDAQ in 2018, which provided capital for further research and development. The company has evolved by progressing its lead drug candidates through preclinical and early clinical development stages, aiming to address unmet medical needs in various therapeutic areas.
Core Business Areas
- Oral Peptide Therapeutics Development: Entera Bio Ltd. is dedicated to developing and commercializing oral formulations of peptide drugs. This involves leveraging proprietary drug delivery technology to enable peptides, which are typically administered via injection, to be taken orally. The goal is to improve patient compliance and convenience.
Leadership and Structure
Entera Bio Ltd. is led by a management team with expertise in drug development and biopharmaceutical operations. The organizational structure is typical of a clinical-stage biotech company, with functional departments covering research and development, clinical operations, regulatory affairs, and business development. Specific leadership details (CEO, CFO, etc.) would require current company filings or official website information.
Top Products and Market Share
Key Offerings
- EB1014 (Oral PTH): A proprietary oral formulation of parathyroid hormone (PTH) designed for the treatment of osteoporosis. Entera Bio's platform aims to enable oral delivery of PTH, a hormone currently administered by injection. The market for osteoporosis treatments is competitive, with major players offering injectable and oral bisphosphonates, as well as injectable PTH analogs. Specific market share for EB1014 is not yet established as it is in clinical development. Key competitors in the osteoporosis space include Amgen (Prolia/Xgeva), Eli Lilly (Forteo/Trulicity), and Radius Health (Tymlos).
- EB1010 (Oral GLP-1): An oral formulation of a GLP-1 analog intended for the treatment of type 2 diabetes. This product aims to compete in the large and growing diabetes market, offering an oral alternative to injectable GLP-1 receptor agonists. Competitors include Novo Nordisk (Ozempic, Rybelsus), Eli Lilly (Trulicity, Mounjaro), and AstraZeneca (Victoza). Market share for EB1010 is not yet established.
Market Dynamics
Industry Overview
Entera Bio Ltd. operates within the biopharmaceutical industry, specifically in the niche of oral peptide delivery. This sector is characterized by high R&D costs, long development timelines, stringent regulatory requirements, and significant competitive pressures. The demand for novel drug delivery systems that improve patient outcomes and compliance is a key driver.
Positioning
Entera Bio Ltd.'s unique positioning lies in its proprietary technology platform for oral peptide delivery. This platform allows the company to develop oral versions of existing injectable peptide drugs and potentially new peptide-based therapeutics. Its competitive advantage stems from the potential to offer more convenient and cost-effective treatment options, thereby improving patient adherence and potentially expanding market reach.
Total Addressable Market (TAM)
The TAM for osteoporosis treatments is substantial, estimated to be in the tens of billions of dollars globally, with continued growth driven by an aging population. The type 2 diabetes market is even larger, exceeding hundreds of billions of dollars. Entera Bio Ltd. is positioned to capture a segment of these markets if its oral peptide formulations achieve regulatory approval and demonstrate efficacy and safety comparable to or better than existing treatments. Currently, the company's market share within these TAMs is negligible as its products are in development.
Upturn SWOT Analysis
Strengths
- Proprietary oral peptide delivery technology platform.
- Potential to develop oral versions of existing blockbuster injectable drugs.
- Experienced management team in drug development.
- Focus on high-need therapeutic areas like osteoporosis and diabetes.
Weaknesses
- Clinical-stage company with no approved products, leading to significant financial burn.
- Reliance on successful completion of clinical trials and regulatory approvals.
- Limited manufacturing capacity for commercial scale production.
- Potential for challenges in scaling up the oral delivery technology.
Opportunities
- Partnerships and collaborations with larger pharmaceutical companies for co-development and commercialization.
- Expansion of the technology platform to other peptide therapeutics.
- Addressing unmet patient needs with more convenient treatment options.
- Leveraging the growing market for metabolic and bone health treatments.
Threats
- Failure to demonstrate efficacy or safety in clinical trials.
- Intense competition from established pharmaceutical companies and emerging biotechs.
- Regulatory hurdles and delays in drug approval processes.
- Intellectual property challenges and patent expirations.
- Funding risks associated with extended clinical development.
Competitors and Market Share
Key Competitors
- Novo Nordisk A/S (NVO)
- Eli Lilly and Company (LLY)
- Amgen Inc. (AMGN)
- AstraZeneca PLC (AZN)
Competitive Landscape
Entera Bio Ltd. faces intense competition from large, established pharmaceutical companies with significant R&D budgets, established distribution networks, and proven track records. Its advantage lies in its disruptive oral delivery technology, which could offer a significant improvement over existing injectable therapies. However, it must overcome the challenge of proving the safety and efficacy of its novel formulations in rigorous clinical trials and navigating the complex regulatory landscape.
Growth Trajectory and Initiatives
Historical Growth: Entera Bio Ltd.'s historical growth has been characterized by its progression from a preclinical company to a clinical-stage entity, marked by the advancement of its lead drug candidates and securing financing through IPOs and subsequent offerings.
Future Projections: Future growth projections are heavily dependent on the successful outcomes of its ongoing and planned clinical trials, particularly for EB1014 and EB1010. Analyst estimates, if available, would provide insights into potential revenue upon commercialization and market penetration. The overall trajectory is contingent on regulatory approvals and market adoption.
Recent Initiatives: Recent initiatives likely include advancing its lead drug candidates (EB1014 and EB1010) into later-stage clinical trials, exploring potential strategic partnerships, and managing its cash runway through prudent financial management and potentially further fundraising efforts.
Summary
Entera Bio Ltd. is a clinical-stage biopharmaceutical company with a promising proprietary oral peptide delivery technology. Its core strength lies in the potential to transform injectable peptide therapeutics into oral medications, addressing significant unmet needs in areas like osteoporosis and diabetes. However, it faces substantial risks associated with clinical trial failures, intense competition from established giants, and the inherent financial demands of drug development. Success hinges on successful clinical outcomes and strategic partnerships to navigate the path to commercialization.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings with the U.S. Securities and Exchange Commission (SEC)
- Reputable financial news outlets
- Industry research reports
- Company investor relations materials
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investing in clinical-stage biotechnology companies involves significant risks. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Entera Bio Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-06-28 | CEO & Director Ms. Miranda J. Toledano M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 20 | Website https://www.enterabio.com |
Full time employees 20 | Website https://www.enterabio.com | ||
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.